{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:06:46Z","timestamp":1789135606978,"version":"build-2803163510"},"reference-count":56,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inadequate targeting, short-lived therapeutic exposure, drug resistance, and toxicities limit effective cancer treatments. We developed a strategy that redirects an evolutionarily optimized clotting cascade to achieve selective, sustained drug deposition within solid tumors. A vascular disrupting agent induces tumor-specific endothelial injury, activating platelets and exposing fibrinogen-binding sites. Systemically administered fibrinogen\u2013drug nanoparticles (FDNs) bind activated platelets with multivalent avidity, amplify thrombus formation, and become immobilized within tumor vessels, creating an intratumoral drug depot that maintains drug concentrations far above cytotoxic levels for over 10 days. A single 20 min treatment induced durable complete remissions in most mice bearing subcutaneous triple-negative breast or pancreatic tumors. This novel vascular-targeted approach enhances selective intratumoral drug localization through multivalent platelet binding, embolization, and sustained drug release to combat refractory cancers.<\/jats:p>","DOI":"10.1021\/acsptsci.6c00337","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T07:46:30Z","timestamp":1787471190000},"page":"2628-2638","source":"Crossref","is-referenced-by-count":0,"title":["Fibrinogen\u2013Drug\nNanoparticles Achieve Durable\nResponses in Pancreatic and Breast Cancer Murine Models"],"prefix":"10.1021","volume":"9","author":[{"given":"Rose","family":"Razavi","sequence":"first","affiliation":[{"name":"Nanoprobes, Inc. , , ,","place":["Yaphank, New York, United States, 11980"]},{"name":"University of Pennsylvania , , , ,","place":["Philadelphia, Pennsylvania, United States, 19104"]},{"name":"University of Pennsylvania , , , ,","place":["Philadelphia, Pennsylvania, United States, 19104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Nanoprobes, Inc. , , ,","place":["Yaphank, New York, United States, 11980"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-6233","authenticated-orcid":true,"given":"James F.","family":"Hainfeld","sequence":"additional","affiliation":[{"name":"Nanoprobes, Inc. , , ,","place":["Yaphank, New York, United States, 11980"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"12","key":"2026091109134391800_cit1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers\nas an Emerging Platform\nfor Cancer Therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"issue":"8","key":"2026091109134391800_cit2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug Penetration in Solid Tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"2026091109134391800_cit3","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","article-title":"Meta-Analysis of Nanoparticle\nDelivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling\nand Simulation Approach","volume":"14","author":"Cheng","year":"2020","journal-title":"ACS Nano"},{"issue":"5","key":"2026091109134391800_cit4","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of Nanoparticle Delivery\nto Tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"2026091109134391800_cit5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-Drug Conjugate\nSacituzumab Govitecan Drives\nEfficient Tissue Penetration and Rapid Intracellular Drug Release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"2026091109134391800_cit6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold Tumors:\nA Therapeutic Challenge for Immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front.\nImmunol."},{"issue":"7","key":"2026091109134391800_cit7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-cancerbio-061421-040258","article-title":"Strategies\nfor Heating Up Cold Tumors\nto Boost Immunotherapies","volume":"7","author":"Zabransky","year":"2023","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"12","key":"2026091109134391800_cit8","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of Resistance to Antibody-Drug\nConjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"2026091109134391800_cit9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nmat3049","article-title":"Nanoparticles That Communicate in\nVivo to Amplify Tumour Targeting","volume":"10","author":"von Maltzahn","year":"2011","journal-title":"Nature Mater"},{"issue":"1","key":"2026091109134391800_cit10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1039\/C5SC01698C","article-title":"A Cooperative Polymeric Platform\nfor Tumor-Targeted Drug Delivery","volume":"7","author":"Song","year":"2016","journal-title":"Chem. Sci."},{"key":"2026091109134391800_cit11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1101\/sqb.2009.74.001","article-title":"Step-by-Step\nEvolution of Vertebrate Blood Coagulation","volume":"74","author":"Doolittle","year":"2009","journal-title":"Cold\nSpring Harb Symp. Quant Biol."},{"issue":"3","key":"2026091109134391800_cit12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4062\/biomolther.2016.138","article-title":"Platelet\nShape Changes and Cytoskeleton Dynamics as Novel Therapeutic Targets\nfor Anti-Thrombotic Drugs","volume":"25","author":"Shin","year":"2017","journal-title":"Biomol. Ther."},{"key":"2026091109134391800_cit13","doi-asserted-by":"publisher","first-page":"102768","DOI":"10.1016\/j.cis.2022.102768","article-title":"Ultrasound-Modified Protein-Based Colloidal Particles:\nInterfacial Activity, Gelation Properties, and Encapsulation Efficiency","volume":"309","author":"Mozafarpour","year":"2022","journal-title":"Adv. Colloid Interface Sci."},{"issue":"4","key":"2026091109134391800_cit14","first-page":"275","article-title":"Multifunctional\nRoles of Thrombin","volume":"29","author":"Narayanan","year":"1999","journal-title":"Ann. Clin. Lab Sci."},{"key":"2026091109134391800_cit15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-1-62703-339-8_14","article-title":"Fibrinogen","volume":"992","author":"Stang","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"2026091109134391800_cit16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00441-008-0646-0","article-title":"Vascular Targeted Therapies in Oncology","volume":"335","author":"Siemann","year":"2009","journal-title":"Cell Tissue Res."},{"issue":"1","key":"2026091109134391800_cit17","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1259\/bjr\/36205483","article-title":"Tumour Vascular\nDisrupting Agents: Combating Treatment\nResistance","volume":"81","author":"Tozer","year":"2008","journal-title":"Br J. Radiol."},{"issue":"6","key":"2026091109134391800_cit18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1628","article-title":"Disrupting\nTumour Blood Vessels","volume":"5","author":"Tozer","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"2026091109134391800_cit19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/jps.1085","article-title":"Carrier\nProteins Determine Local Pharmacokinetics and Arterial Distribution\nof Paclitaxel","volume":"90","author":"Lovich","year":"2001","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"2026091109134391800_cit20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080580","article-title":"Novel Pancreatic Cancer Cell Lines Derived from Genetically\nEngineered Mouse Models of Spontaneous Pancreatic Adenocarcinoma:\nApplications in Diagnosis and Therapy","volume":"8","author":"Torres","year":"2013","journal-title":"PLoS\nOne"},{"issue":"1","key":"2026091109134391800_cit21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pan.2019.11.006","article-title":"Differences\nbetween KC and KPC Pancreatic Ductal Adenocarcinoma Mice Models, in\nTerms of Their Modeling Biology and Their Clinical Relevance","volume":"20","author":"Ariston Gabriel","year":"2020","journal-title":"Pancreatology"},{"issue":"3","key":"2026091109134391800_cit22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/cancers13030440","article-title":"Preclinical\nModels of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy\nStudies","volume":"13","author":"Pham","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"2026091109134391800_cit23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.chembiol.2005.09.010","article-title":"Microtubule\nInteractions with Chemically Diverse Stabilizing Agents: Thermodynamics\nof Binding to the Paclitaxel Site Predicts Cytotoxicity","volume":"12","author":"Buey","year":"2005","journal-title":"Chem. Biol."},{"issue":"1","key":"2026091109134391800_cit24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15171\/apb.2018.010","article-title":"Investigation of Effective Parameters on Size of Paclitaxel Loaded\nPLGA Nanoparticles","volume":"8","author":"Madani","year":"2018","journal-title":"Adv. Pharm. Bull."},{"issue":"14","key":"2026091109134391800_cit25","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1158\/1078-0432.CCR-05-0227","article-title":"In Vivo Evaluation of 177Lu- and 67\/64Cu-Labeled Recombinant\nFragments of Antibody chCE7 for Radioimmunotherapy and PET Imaging\nof L1-CAM-Positive Tumors","volume":"11","author":"Gru\u0308nberg","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"2026091109134391800_cit26","volume-title":"Acute Toxicity of\nPolyethylene Glycol 200 in Laboratory Animals"},{"issue":"19","key":"2026091109134391800_cit27","doi-asserted-by":"publisher","first-page":"10698","DOI":"10.1016\/S0021-9258(19)85139-6","article-title":"Reconstitution of the Purified Platelet Fibrinogen\nReceptor. Fibrinogen Binding Properties of the Glycoprotein IIb-IIIa\nComplex","volume":"260","author":"Parise","year":"1985","journal-title":"J. Biol. Chem."},{"key":"2026091109134391800_cit28","volume-title":"Comprehensive\nBiomaterials II","author":"Ducheyne","year":"2017"},{"issue":"2","key":"2026091109134391800_cit29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1258\/cvd.2012.012007","article-title":"The Platelet Fibrinogen Receptor:\nFrom Megakaryocyte to the Mortuary","volume":"1","author":"Floyd","year":"2012","journal-title":"JRSM Cardiovasc.\nDis."},{"issue":"2","key":"2026091109134391800_cit30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1152\/physiol.00020.2016","article-title":"New Concepts and Mechanisms\nof Platelet Activation Signaling","volume":"32","author":"Estevez","year":"2017","journal-title":"Physiology"},{"issue":"5","key":"2026091109134391800_cit31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1161\/CIRCRESAHA.110.232678","article-title":"Molecular Imaging of Coronary Atherosclerosis and Myocardial\nInfarction","volume":"108","author":"Leuschner","year":"2011","journal-title":"Circ. Res."},{"issue":"9\u201310","key":"2026091109134391800_cit32","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.bbabio.2006.06.014","article-title":"Necrosis, a Well-Orchestrated Form\nof Cell Demise: Signalling Cascades, Important Mediators and Concomitant\nImmune Response","volume":"1757","author":"Festjens","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"2026091109134391800_cit100","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jconrel.2012.07.043","article-title":"A Docetaxel-Carboxymethylcellulose\nNanoparticle Outperforms the Approved Taxane Nanoformulation, Abraxane,\nin Mouse Tumor Models with Significant Control of Metastases","volume":"162","author":"Ernsting","year":"2012","journal-title":"J Control Release"},{"issue":"1\u20132","key":"2026091109134391800_cit54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijpharm.2007.02.011","article-title":"Enhanced\nSolubility and Stability\nof PEGylated Liposomal Paclitaxel: In Vitro and in Vivo Evaluation","volume":"338","author":"Yang","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"48","key":"2026091109134391800_cit33","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The Emergence\nof Trophoblast Cell-Surface\nAntigen 2 (TROP-2) as a Novel Cancer Target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"2026091109134391800_cit34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/bjc.1993.488","article-title":"Cytotoxic Studies\nof Paclitaxel (Taxol) in Human Tumour\nCell Lines","volume":"68","author":"Liebmann","year":"1993","journal-title":"Br. J. Cancer"},{"issue":"2","key":"2026091109134391800_cit35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1593\/neo.06748","article-title":"Visualizing the\nAcute Effects of Vascular-Targeted\nTherapy in Vivo Using Intravital Microscopy and Magnetic Resonance\nImaging: Correlation with Endothelial Apoptosis, Cytokine Induction,\nand Treatment Outcome","volume":"9","author":"Seshadri","year":"2007","journal-title":"Neoplasia"},{"key":"2026091109134391800_cit36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug Resistance in Cancer: Understanding\nMolecular Mechanisms, Immunoprevention and Therapeutic Approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"2026091109134391800_cit37","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/cbdd.13166","article-title":"An Overview on Vadimezan (DMXAA): The Vascular Disrupting\nAgent","volume":"91","author":"Daei Farshchi Adli","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"2026091109134391800_cit38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/157489207779561462","article-title":"Small Molecule\nVascular Disrupting Agents: Potential New Drugs for Cancer Treatment","volume":"2","author":"Cai","year":"2007","journal-title":"PRA"},{"issue":"13","key":"2026091109134391800_cit39","doi-asserted-by":"publisher","first-page":"15444","DOI":"10.18632\/oncotarget.6999","article-title":"Tumor Resistance to\nVascular Disrupting Agents: Mechanisms,\nImaging, and Solutions","volume":"7","author":"Liang","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"2026091109134391800_cit40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099988","article-title":"DMXAA Causes Tumor\nSite-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer,\nand like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist,\n2\u20193\u2032-cGAMP, Induces M2Macrophage Repolarization","volume":"9","author":"Downey","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"2026091109134391800_cit41","doi-asserted-by":"publisher","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","article-title":"Trial Watch: STING Agonists in Cancer Therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"2026091109134391800_cit42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1535-6108(02)00238-6","article-title":"Integrin-Mediated\nTargeting\nof Drug Delivery to Irradiated Tumor Blood Vessels","volume":"3","author":"Hallahan","year":"2003","journal-title":"Cancer Cell"},{"issue":"3","key":"2026091109134391800_cit43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3109\/02656739409010278","article-title":"Endothelial Cells and Hyperthermia","volume":"10","author":"Fajardo","year":"1994","journal-title":"Int. J. Hyperthermia"},{"issue":"6","key":"2026091109134391800_cit44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/0301-5629(94)90093-0","article-title":"Shock Wave Induced Endothelial Damage\u2500In\nSitu Analysis by Confocal Laser Scanning Microscopy","volume":"20","author":"Seidl","year":"1994","journal-title":"Ultrasound Med. Biol."},{"issue":"11","key":"2026091109134391800_cit45","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.3390\/cancers13112695","article-title":"STING Agonists\nas Cancer Therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"2026091109134391800_cit46","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1038\/s41467-021-25393-x","article-title":"Tumour-Targeted Interleukin-12 and\nEntinostat Combination\nTherapy Improves Cancer Survival by Reprogramming the Tumour Immune\nCell Landscape","volume":"12","author":"Hicks","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"2026091109134391800_cit47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using Immunotherapy\nto Boost the Abscopal Effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"2026091109134391800_cit48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122595119","article-title":"A Single Local\nDelivery of Paclitaxel and Nucleic Acids via an Immunoactive Polymer\nEliminates Tumors and Induces Antitumor Immunity","volume":"119","author":"Meng","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"2026091109134391800_cit49","first-page":"5","article-title":"Angiogenesis:\nAn Update and Potential Drug Approaches (Review)","volume":"36","author":"Abdelrahim","year":"2010","journal-title":"Int. J. Oncol"},{"issue":"2","key":"2026091109134391800_cit50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2019.236901","article-title":"Fibrin(Ogen)\nin Human Disease: Both Friend and Foe","volume":"105","author":"Vilar","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2026091109134391800_cit51","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/jth.13283","article-title":"Coagulopathy and Its Management in\nPatients with Severe Burns","volume":"14","author":"Glas","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"2026091109134391800_cit52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.14573\/altex.2003311","article-title":"Associations\nbetween Clinical Signs and Pathological\nFindings in Toxicity Testing","volume":"38","author":"Silva","year":"2021","journal-title":"ALTEX"},{"issue":"1\u20132","key":"2026091109134391800_cit53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jpba.2005.02.023","article-title":"Sensitive HPLC Method\nfor Quantitation of Paclitaxel (Genexol in Biological Samples with\nApplication to Preclinical Pharmacokinetics and Biodistribution","volume":"39","author":"Kim","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"2026091109134391800_cit56","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1021\/mp500817h","article-title":"Release Kinetics Study\nof Poorly Water-Soluble Drugs from Nanoparticles: Are We Doing It\nRight?","volume":"12","author":"Abouelmagd","year":"2015","journal-title":"Mol. Pharmaceutics"}],"container-title":["ACS Pharmacology &amp; Translational\nScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsptsci.6c00337","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/9\/9\/2628\/67027086\/acsptsci.6c00337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/9\/9\/2628\/67027086\/acsptsci.6c00337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:14:04Z","timestamp":1789132444000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article\/9\/9\/2628\/5289696\/Fibrinogen-Drug-Nanoparticles-Achieve-Durable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,21]]},"published-print":{"date-parts":[[2026,9,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acsptsci.6c00337","relation":{},"ISSN":["2575-9108"],"issn-type":[{"value":"2575-9108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}